MX2020003742A - Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos. - Google Patents

Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.

Info

Publication number
MX2020003742A
MX2020003742A MX2020003742A MX2020003742A MX2020003742A MX 2020003742 A MX2020003742 A MX 2020003742A MX 2020003742 A MX2020003742 A MX 2020003742A MX 2020003742 A MX2020003742 A MX 2020003742A MX 2020003742 A MX2020003742 A MX 2020003742A
Authority
MX
Mexico
Prior art keywords
porcine
csf
variants
csf variants
pigs
Prior art date
Application number
MX2020003742A
Other languages
English (en)
Inventor
Peter Connor Canning
Nickolas Knudsen
Md Harunur Rashid
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2020003742A publication Critical patent/MX2020003742A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a variantes del factor estimulador de colonias de granulocitos de porcino (pG-CSF); las variantes del pG-CSF son útiles en el tratamiento para prevenir o reducir la incidencia de infecciones bacterianas en cerdos; se describen también métodos de tratamiento de los cerdos.
MX2020003742A 2017-10-11 2018-10-10 Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos. MX2020003742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570877P 2017-10-11 2017-10-11
PCT/US2018/055203 WO2019075053A1 (en) 2017-10-11 2018-10-10 PORCINE G-CSF VARIANTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020003742A true MX2020003742A (es) 2020-10-28

Family

ID=66101096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003742A MX2020003742A (es) 2017-10-11 2018-10-10 Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.

Country Status (13)

Country Link
US (2) US11578111B2 (es)
EP (1) EP3694535A4 (es)
JP (1) JP7046173B2 (es)
KR (2) KR102461760B1 (es)
CN (1) CN111565736B (es)
AR (1) AR113756A1 (es)
AU (2) AU2018348138A1 (es)
BR (1) BR112020007037A2 (es)
CA (1) CA3077215A1 (es)
MX (1) MX2020003742A (es)
RU (1) RU2020113060A (es)
TW (1) TWI820046B (es)
WO (1) WO2019075053A1 (es)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
EP0347041A3 (en) * 1988-05-13 1990-11-22 Amgen Inc. Compositions and method for treating or preventing infections in animals
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
AU3515001A (en) * 1993-01-28 2001-06-28 Amgen, Inc. G-CSF analog compositions
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
RU2273645C9 (ru) * 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
CA2452540A1 (en) * 1996-10-15 1998-04-23 Amgen Inc. Keratinocyte growth factor-2 products
EP1144998A3 (en) * 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
KR100689212B1 (ko) 1999-01-29 2007-03-09 암겐 인코포레이티드 Ｇｃｓｆ 결합체
US7323174B1 (en) * 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
KR20040069980A (ko) * 2001-06-22 2004-08-06 파마시아 코포레이션 화학적으로 변형된 프로게니포이에틴 접합체
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2381104T3 (es) * 2001-10-29 2012-05-23 Crucell Holland B.V. Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
MXPA05012099A (es) 2003-05-09 2006-02-08 Schering Ag Tratamiento de enfermedades respiratorias inflamatorias.
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
CN101014616A (zh) * 2004-07-26 2007-08-08 埃斯特瑞恩有限公司 接头分子
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
JP4788646B2 (ja) * 2007-04-26 2011-10-05 トヨタ自動車株式会社 蓄電装置及び車両
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
US20110182848A1 (en) * 2007-08-03 2011-07-28 Asterion Limited Granulocyte colony stimulating factor
AU2013202836B8 (en) * 2008-07-23 2015-07-30 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
UA103774C2 (uk) 2008-07-23 2013-11-25 Амбркс, Інк. Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
WO2010096446A1 (en) * 2009-02-17 2010-08-26 Marc Fisher Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
EP2525787B1 (en) * 2010-01-19 2017-03-15 Hanmi Science Co., Ltd. Liquid formulations for long-acting g-csf conjugate
WO2011163460A1 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012171057A1 (en) * 2011-06-13 2012-12-20 Csl Limited Antibodies against g-csfr and uses thereof
CN104114183A (zh) * 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
CA2868477A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods

Also Published As

Publication number Publication date
EP3694535A1 (en) 2020-08-19
AU2021204727B2 (en) 2023-02-09
AU2021204727A1 (en) 2021-08-05
US11578111B2 (en) 2023-02-14
KR20200066628A (ko) 2020-06-10
US20230340051A1 (en) 2023-10-26
US20210054039A1 (en) 2021-02-25
JP2020536935A (ja) 2020-12-17
KR102619071B1 (ko) 2023-12-27
WO2019075053A1 (en) 2019-04-18
TW201928058A (zh) 2019-07-16
EP3694535A4 (en) 2021-07-28
AU2018348138A1 (en) 2020-04-23
CN111565736B (zh) 2024-03-08
AR113756A1 (es) 2020-06-10
CA3077215A1 (en) 2019-04-18
BR112020007037A2 (pt) 2020-11-17
RU2020113060A (ru) 2021-11-12
KR20220150432A (ko) 2022-11-10
JP7046173B2 (ja) 2022-04-01
RU2020113060A3 (es) 2021-12-27
TWI820046B (zh) 2023-11-01
CN111565736A (zh) 2020-08-21
KR102461760B1 (ko) 2022-10-31

Similar Documents

Publication Publication Date Title
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
PH12016501512A1 (en) Treatment for resistant acne
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
ZA202002093B (en) Antibacterial compounds
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
EA202092824A1 (ru) Комбинированная терапия
PL3476397T3 (pl) Nowe kompozycje i ich zastosowanie w leczeniu zakażeń bakteryjnych
DK3285787T3 (da) Behandling af bakterieinfektioner i akvakultur
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
ZA202000884B (en) Compositions for treating skin and mucous membrane infections
MX2020003742A (es) Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.